WAVEMAN · COMPANY

SRPT · Sarepta Therapeutics, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

SRPT

Name: Sarepta Therapeutics, Inc. (SRPT) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Sarepta Therapeutics, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000873303

SEC FILINGS☆ WATCH

INSIDER NET · 180D

-$123.2K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

154

13F, latest reported quarter

REVENUE GROWTH

+4.3%

XBRL, annual

NET MARGIN

-38.3%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$123.2K over 180 days

more than 54% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

154 funds added or opened last quarter

more than 79% of Pharma & Biotech

REVENUE

+4.3% year over year

more than 53% of Pharma & Biotech

MARGIN

-38.3% net margin

below 55% of Pharma & Biotech

BUYBACKS

$25.0M repurchased, FY to 2025-12-31

below 58% of Pharma & Biotech

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

154 funds added or opened positions in the latest 13F quarter, of 330 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +27.8%

+27.8%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $123.2K sold by insiders over 180 days, 154 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Sarepta Therapeutics, Inc. insiders sold a net $123.2K of stock across 53 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Mayo Stephen

Director

SELL

2026-03-12

7,239.0

$123.2K

Estepan Ian Michael

Chief Operating Officer

SELL

2025-12-16

13,187.0

$294.2K

Nicaise Claude

Director

SELL

2025-03-12

2,491.0

$248.2K

Wigzell Hans Lennart Rudolf

Director

SELL

2024-12-12

10,500.0

$1.3M

Boor Kathryn Jean

Director

SELL

2024-12-05

1,636.0

$205.4K

53 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 48 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

18,994,958.0 sh

$341.3M

STATE STREET CORP

8,916,090.0 sh

$160.2M

VANGUARD PORTFOLIO MANAGEMENT LLC

8,377,470.0 sh

$150.5M

TWO SIGMA INVESTMENTS, LP

4,598,735.0 sh

$82.6M

VANGUARD CAPITAL MANAGEMENT LLC

4,591,755.0 sh

$82.5M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Moonvest ETF

$2.6M POSITION · AS OF 2026-04-30

5.9%

First Trust NYSE Arca Biotechnology Index Fund

$73.6M POSITION · AS OF 2026-03-31

3.2%

Virtus Biotech Etf

$917.8K POSITION · AS OF 2026-04-30

1.5%

Global X Genomics & Biotechnology ETF

$686.8K POSITION · AS OF 2026-02-28

1.3%

First Trust Health Care AlphaDEX Fund

$10.9M POSITION · AS OF 2026-04-30

1.2%

ALPS Medical Breakthroughs ETF

$1.6M POSITION · AS OF 2026-02-28

1.1%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 28 registered trials, 13 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

3 ACTIVE

Phase 2

0 ACTIVE

Phase 3

4 ACTIVE

Phase 4

1 ACTIVE

Not applicable

3 ACTIVE

Multi-phase

2 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$7.8M

-$17.3M

$3.8M

-87%

+25%

2024

$2.0M

-$14.5M

$2.7M

-29%

-6%

2023

$1.7M

-$34.6M

$3.6M

-43%

-6%

2022

$124.9M

$162.9M

$4.6M

-24%

-10%

2021

$1.5M

-$304.8M

$6.3M

-47%

+0%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2025-09	2024-12	2023-12
REVENUE	$1.9B	—	$1.8B	$1.1B
OPERATING INCOME	$-699.8M	—	$218.1M	$-267.8M
NET INCOME	$-713.4M	—	$235.2M	$-536.0M
EPS (DILUTED)	-7.13	—	2.34	-5.80
OPERATING CASH FLOW	$-205.5M	—	$-205.8M	$-501.0M
CASH	$801.3M	—	$1.1B	$428.4M
LONG-TERM DEBT	$829.0M	$140.5M	$1.1B	$1.2B
BUYBACKS	$25.0M	—	$0	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE